Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

96°
- Benton, AR (72018)
  Today
  
  Sunshine and clouds mixed. Continued hot and humid. High 97F. Winds SW at 10 to 15 mph..
  
  Tonight
  
  Partly cloudy. A stray shower or thunderstorm is possible. Low 77F. Winds WSW at 5 to 10 mph.
  
  Updated: July 31, 2026 @ 2:10 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2026
Community Calendar

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

1.055 -0.055 (-4.95%)

Streaming Delayed Price Updated: 3:29 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Latest Analyst Ratings for ADC Therapeutics ↗

January 24, 2023

Via Benzinga

Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 13, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 12, 2023

Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity...

Via Benzinga

4 Analysts Have This to Say About ADC Therapeutics ↗

January 04, 2023

Via Benzinga

Analyst Ratings for ADC Therapeutics ↗

November 09, 2022

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

Via Benzinga

Analyst Ratings for ADC Therapeutics ↗

September 09, 2022

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

Via Benzinga

TSMC, CommScope Holding And Other Big Stocks Moving Higher On Thursday ↗

January 12, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer

January 03, 2023

From ADC Therapeutics SA

Via Business Wire

Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 21, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 21, 2022

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday

Via InvestorPlace

Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket ↗

December 21, 2022

Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed...

Via Benzinga

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

December 21, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

December 19, 2022

From ADC Therapeutics SA

Via Business Wire

Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal ↗

December 04, 2022

Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built...

Via Talk Markets

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

November 28, 2022

From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022 ↗

November 09, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

November 28, 2022

On Monday, 79 companies reached new 52-week lows.

Via Benzinga

ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 08, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

November 07, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

November 03, 2022

From ADC Therapeutics SA

Via Business Wire

IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma

November 02, 2022

From ADC Therapeutics SA

Via Business Wire

November 02, 2022

From IGM Biosciences, Inc.

Via GlobeNewswire

ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer

November 01, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

October 31, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

September 21, 2022

From ADC Therapeutics SA

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022 ↗

September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago...

Via Benzinga

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

September 16, 2022

From ADC Therapeutics SA

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

September 14, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

September 13, 2022

From The Schall Law Firm

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

ADC Therapeutics SA Common Shares (NY:ADCT)

All News about ADC Therapeutics SA Common Shares

Sections

Services

Follow Us